ClinicalTrials.gg
RecruitingNCT07090070p53 RCTUpdated Sep 8, 2026

Evaluating Treatment Strategies for p53 Mutant Oral Cancer and Oral Cancer Precursors

An interventional study of Cohort 1 Intervention group and Cohort 2 severe/CIS margins clear in Oral Epithelial Dysplasia (OED) and Oral Squamous Cell Carcinoma (SCC), sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
636
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 164 studies in Squamous Cell Carcinoma of Head and Neck with a site in Canada — 30 open to participants now, 57 under way, 13 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Canada.

Planned enrollment
18th of 149
636 · median 129
Started
2026
with 4 others
No phase
16 of 164
7 open now
Primary completion
2032-01
later than 56 of 56 live
Registered
158th of 164
by date

Among the 164 studies in Squamous Cell Carcinoma of Head and Neck with a site in Canada, this one is the 18th largest by planned enrollment of the 149 interventional ones that give a count, is one of 5 that started in 2026, is one of 16 with no phase, reaches primary completion later than 56 of the 56 other live ones, and was the 158th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

30 of the 164 studies in Squamous Cell Carcinoma of Head and Neck with a site in Canada are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Squamous Cell Carcinoma of Head and Neck with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical trial is to optimize treatment strategies for patients with p53-mutant oral epithelial dysplasia (OED) and early-stage oral squamous cell carcinoma (OSCC). The main question it aims to answer is what the most optimal treatment is at each diagnostic stage. It is hypothesized that lesions with p53-abnormal low-grade dysplasia (LGD) without surgical intervention will progress to high-grade dysplasia (HGD) or SCC in 4 years. It is also predicted that a clear p53 and severe/CIS excision margins in patients with p53-abnormal HGD will reduce the progression to invasive SCC, compared to clear severe/CIS margins, within 4 years. Finally, it is thought that patients with p53-abnormal cT1N0 and DOI\<4mm receiving an END will have improved disease free and overall survival. This research will elucidate whether or not these hypotheses are correct.

Participants in each diagnostic cohort will be assigned to one of two different treatment options, listed below:

Cohort 1:

A) No intervention, observation only B) Surgical excision with clear margins

Cohort 2:

A) Surgical excision with clear severe/CIS margins B) Surgical excision with clear severe/CIS and p53 margins

Cohort 3:

A) Surgical excision and elective neck dissection (END) B) Surgical excision and close follow-up, only salvage ND if development of nodal disease

03

Conditions studied

  • Oral Epithelial Dysplasia (OED)
  • Oral Squamous Cell Carcinoma (SCC)

Keywords

  • p53 mutant
  • SCC
  • oral epithelial dysplasia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults age 18 or over
  • No history of head and neck radiation
  • p53-abnormal IHC patterns (surrogate marker for TP53 mutation)

Cohort 1:

  • -confirmed mild/moderate dysplasia

Cohort 2:

  • Biopsy-confirmed severe dysplasia or CIS

Cohort 3:

  • T1 SCC with depth of Invasion (DOI) \<4mm
  • Clinically and radiologically node-negative (confirmed by contrast-enhanced CT)

Exclusion criteria

Exclusion Criteria:

  • status
  • Lesions greater than 3 cm
  • Presence of Proliferative Verrucous Leukoplakia

Cohort 1:

  • Had prior treatment for oral premalignant lesions

Cohort 2:

  • Presence of invasive SCC on initial

Cohort 3:

  • Positive nodes on contrast-enhanced CT
  • DOI >= 4mm
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
636 participants (estimated)

Study arms

  • No intervention
    Cohort 1: p53 mutant mild/moderate dysplasia observational group

    Observation only

  • Experimental
    Cohort 1: p53 mutant mild/moderate dysplasia excision group

    Clear margin excision of the lesion under local anesthetic, with re-excision for p53-positive margins

    Procedure: Cohort 1 Intervention group

  • Active comparator
    Cohort 2: p53 mutant Severe/CIS dysplasia clear severe/CIS margin group

    Clear margin excision of the lesion under local anesthetic, with re-excision until severe/CIS margins are clear

    Procedure: Cohort 2 severe/CIS margins clear

  • Experimental
    Cohort 2: p53 mutant Severe/CIS dysplasia negative p53 and severe/CIS margin group

    Excision of the lesion ensuring final negative p53 and severe/CIS margins

    Procedure: Cohort 2 p53 and severe/CIS margins clear

  • Active comparator
    Cohort 3: p53 mutant T1 SCC (DOI <4mm) excision and END group

    Excision of primary lesion and immediate elective neck dissection (END)

    Procedure: Cohort 3 Excision and END

  • Experimental
    Cohort 3: p53 mutant T1 SCC (DOI <4mm) excision and follow up group

    Excision of primary lesion and close follow up with salvage neck dissection if development of nodal disease

    Procedure: Cohort 3 Excision and Close follow up

Interventions

  • ProcedureCohort 1 Intervention group

    Clear margin excision of the lesion under local anesthetic, with re-excision for p53-positive margins.

  • ProcedureCohort 2 severe/CIS margins clear

    Clear margin excision of the lesion under local anesthetic, with re-excision until severe/CIS margins are clear

  • ProcedureCohort 2 p53 and severe/CIS margins clear

    Excision of the lesion ensuring final negative p53 and severe/CIS margins

  • ProcedureCohort 3 Excision and END

    Excision of primary lesion and immediate elective neck dissection

  • ProcedureCohort 3 Excision and Close follow up

    Excision of primary lesion and close follow up with salvage neck dissection if development of nodal disease

06

What researchers measure

Primary outcomes

  1. Progression of Disease

    Study 1: Whether diagnosis progressed from low-grade dysplasia (mild/moderate OED) to high-grade (severe/CIS) dysplasia or OSCC. Study 2: Whether diagnosis progressed from high-grade (severe/CIS) dysplasia to OSCC.

    Time frame: 4 years

  2. Time of Disease Progression

    Study 1: Time for disease to progress from low-grade dysplasia (mild/moderate OED) to high-grade (severe/CIS) dysplasia or OSCC. Study 2: Time for disease to progress from high-grade (severe/CIS) dysplasia to OSCC.

    Time frame: 4 years

  3. Recurrence of Disease

    Study 1: Whether recurrence of low-grade dysplasia is present. Study 2: Whether recurrence of high-grade dysplasia is present. Study 3: Whether recurrence of OSCC is present, and if recurrence pattern is local recurrence or nodal metastasis. All: Time for disease to recur.

    Time frame: Study 1 and 2: 4 years, Study 3: 3 years

  4. Disease-free Survival

    Study 3: If survival is achieved disease-free following treatment.

    Time frame: 3 years

Secondary outcomes

  1. Overall survival

    Overall survival is measured as survival for 4 years following diagnosis and treatment. Cause of death will be included, if applicable.

    Time frame: Study 1 and 2: 4 years, Study 3: 3 years

  2. Patient Reported Outcomes - Quality of Life and Functional Measurements

    Patient quality of life: 1. Oral Health Impact Profile-14 (OHIP) - 14 questions on a 5 point Likert scale (0-4), total ranging from 0-56, with higher scores indicating worse quality of life. 2. Hospital Anxiety and Depression Scale (HADS) - 14 questions on a 4 point Likert scale (0-3), total ranging from 0-21, with higher scores indicating increased severity or probability of depression and anxiety. Functional measurement: 1\. MD Anderson Dysphagia Inventory (MDADI) - 20 questions on a 5 point Likert scale (1-5), score total ranging from 20-100, with lower scores indicating more severe limitations.

    Time frame: Study 1 and 2: 4 years, Study 3: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • D'Cruz AK, Vaish R, Kapre N, Dandekar M, Gupta S, Hawaldar R, Agarwal JP, Pantvaidya G, Chaukar D, Deshmukh A, Kane S, Arya S, Ghosh-Laskar S, Chaturvedi P, Pai P, Nair S, Nair D, Badwe R; Head and Neck Disease Management Group. Elective versus Therapeutic Neck Dissection in Node-Negative Oral Cancer. N Engl J Med. 2015 Aug 6;373(6):521-9. doi: 10.1056/NEJMoa1506007. Epub 2015 May 31. PubMed 26027881 ↗
  • Liu KY, Durham JS, Wu J, Anderson DW, Prisman E, Poh CF. Nodal Disease Burden for Early-Stage Oral Cancer. JAMA Otolaryngol Head Neck Surg. 2016 Nov 1;142(11):1111-1119. doi: 10.1001/jamaoto.2016.2241. PubMed 27560665 ↗
  • Durham JS, Brasher P, Anderson DW, Yoo J, Hart R, Dort JC, Seikaly H, Kerr P, Rosin MP, Poh CF. Effect of Fluorescence Visualization-Guided Surgery on Local Recurrence of Oral Squamous Cell Carcinoma: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2020 Dec 1;146(12):1149-1155. doi: 10.1001/jamaoto.2020.3147. PubMed 33034628 ↗
  • Hyodo T, Kuribayashi N, Fukumoto C, Komiyama Y, Shiraishi R, Kamimura R, Sawatani Y, Yaguchi E, Hasegawa T, Izumi S, Wakui T, Nakashiro KI, Uchida D, Kawamata H. The mutational spectrum in whole exon of p53 in oral squamous cell carcinoma and its clinical implications. Sci Rep. 2022 Dec 15;12(1):21695. doi: 10.1038/s41598-022-25744-8. PubMed 36522371 ↗
  • Lin TY, Liu KYP, Novack R, Mattu PS, Ng TL, Hoang LN, Prisman E, Poh CF, Ko YCK. Abnormal p53 Immunohistochemical Patterns Are Associated with Regional Lymph Node Metastasis in Oral Cavity Squamous Cell Carcinoma at Time of Surgery. Mod Pathol. 2024 Dec;37(12):100614. doi: 10.1016/j.modpat.2024.100614. Epub 2024 Sep 10. PubMed 39265952 ↗
  • Gleber-Netto FO, Neskey D, Costa AFM, Kataria P, Rao X, Wang J, Kowalski LP, Pickering CR, Dias-Neto E, Myers JN. Functionally impactful TP53 mutations are associated with increased risk of extranodal extension in clinically advanced oral squamous cell carcinoma. Cancer. 2020 Oct 15;126(20):4498-4510. doi: 10.1002/cncr.33101. Epub 2020 Aug 14. PubMed 32797678 ↗
  • Liu KYP, Zhu SY, Harrison A, Chen ZY, Guillaud M, Poh CF. Quantitative nuclear phenotype signatures predict nodal disease in oral squamous cell carcinoma. PLoS One. 2021 Nov 4;16(11):e0259529. doi: 10.1371/journal.pone.0259529. eCollection 2021. PubMed 34735529 ↗
  • Novack R, Zhang L, Hoang LN, Kadhim M, Ng TL, Poh CF, Kevin Ko YC. Abnormal p53 Immunohistochemical Patterns Shed Light on the Aggressiveness of Oral Epithelial Dysplasia. Mod Pathol. 2023 Jul;36(7):100153. doi: 10.1016/j.modpat.2023.100153. Epub 2023 Mar 9. PubMed 36906072 ↗
  • Ko YCK, Liu KYP, Chen E, Zhu SY, Poh CF. p53 Abnormal Oral Epithelial Dysplasias are Associated With High Risks of Progression and Local Recurrence-A Retrospective Study in a Longitudinal Cohort. Mod Pathol. 2024 Dec;37(12):100613. doi: 10.1016/j.modpat.2024.100613. Epub 2024 Sep 10. PubMed 39265950 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jan 2032, 66 months after the start.

Of 115 non-industry interventional studies with no phase under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 90. This study's planned 66 months is above that.

Counting every sponsor, half of 126 studies reached it within 59 months; a quarter within 34 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2025
First posted
Jul 29, 2025
StartActual
Jul 8, 2026
Primary completionEst.
Jan 2032
CompletionEst.
Sep 2032
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07090070
Responsible party
Eitan Prisman (Principal Investigator, University of British Columbia) — Principal investigator
First posted
Jul 29, 2025
Start date
Jul 8, 2026
Primary completion
Jan 2032 (estimated)
Completion
Sep 2032 (estimated)
Last update
Sep 8, 2026

Study contacts

Eitan Prisman
Contact
prisman.eitan@vch.ca
6048754126
Alan Wei
Contact
alan.wei@vch.ca
6048754111 ext. 22935

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion